Jacopo Azzollini

Jacopo Azzollini

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CPCatherine M Phelan
Catherine M Phelan
KKKaroline B Kuchenbaecker
Karoline B Kuchenbaecker
JTJonathan P Tyrer
Jonathan P Tyrer
SKSiddhartha P. Kar
Siddhartha P. Kar
KLKate Lawrenson
Kate Lawrenson
PPPaul Pharoah
Paul Pharoah
Paul Pharoah and colleagues report the results of a large genome-wide association study of ovarian cancer. They identify new susceptibility loci for different epithelial ovarian cancer histotypes and use integrated analyses of genes and regulatory features at each locus to predict candidate susceptibility genes, including OBFC1. To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.

18 May 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HZHaoyu Zhang
Haoyu Zhang
TAThomas U. Ahearn
Thomas U. Ahearn
JLJulie Lecarpentier
Julie Lecarpentier
JBJonathan Beesley
Jonathan Beesley
GQGuanghao Qi
Guanghao Qi
MGMontserrat García-Closas
Montserrat García-Closas

23 October 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AIABCTB Investigators
ABCTB Investigators
RMRoger L Milne
Roger L Milne
EMEmbrace
Embrace
GCGEMO Study Collaborators
GEMO Study Collaborators
HEHebon
Hebon
JSJacques Simard
Jacques Simard
Roger Milne and colleagues conduct a genome-wide association study for estrogen receptor (ER)-negative breast cancer combined with BRCA1 mutation carriers in a large cohort. They identify ten new risk variants and find high genetic correlation between breast cancer risk for BRCA1 mutation carriers and risk of ER-negative breast cancer in the general population. Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease1. We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at P < 5 × 10−8 with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.

15 February 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
TRTimothy R. Rebbeck
Timothy R. Rebbeck
TFTara M. Friebel
Tara M. Friebel
EFEitan Friedman
Eitan Friedman
UHUte Hamann
Ute Hamann
DHDezheng Huo
Dezheng Huo
KNKatherine L. Nathanson
Katherine L. Nathanson

10 July 2017 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JLJulie Lecarpentier
Julie Lecarpentier
VSValentina Silvestri
Valentina Silvestri
KKKaroline B. Kuchenbaecker
Karoline B. Kuchenbaecker
DBDaniel Barrowdale
Daniel Barrowdale
JDJoe Dennis
Joe Dennis
LOLaura Ottini
Laura Ottini
Purpose: BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated—for the first time to our knowledge—associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods: We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of BRCA1/2 mutations by constructing weighted polygenic risk scores (PRSs) using published effect estimates as weights. Results: In male carriers of BRCA1/2 mutations, PRS that was based on 88 female breast cancer susceptibility variants was associated with breast cancer risk (odds ratio per standard deviation of PRS, 1.36; 95% CI, 1.19 to 1.56; P = 8.6 × 10−6). Similarly, PRS that was based on 103 prostate cancer susceptibility variants was associated with prostate cancer risk (odds ratio per SD of PRS, 1.56; 95% CI, 1.35 to 1.81; P = 3.2 × 10−9). Large differences in absolute cancer risks were observed at the extremes of the PRS distribution. For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively. Conclusion: PRSs may provide informative cancer risk stratification for male carriers of BRCA1/2 mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management.

7 January 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GCGEMO Study Collaborators
GEMO Study Collaborators
LFLaura Fachal
Laura Fachal
ECEmbrace Collaborators
Embrace Collaborators
KIKConFab Investigators
KConFab Investigators
HIHEBON Investigators
HEBON Investigators
ADAlison M. Dunning
Alison M. Dunning